艾立布林联合NP方案治疗晚期乳腺癌患者的临床效果  

Clinical effect of aribulin combined with NP regimen in the treatment of patients with advanced breast cancer

作　　者：王琳娜[1] 王迪[2] 董彦宏[1] WANG Linna;WANG Di;DONG Yanhong(Department of Pharmacy Dispensing,the Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Cardiology,the Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第四医院药学部调剂科,150001 [2]哈尔滨医科大学附属第四医院心内科,150001

出　　处：《天津医药》2025年第3期326-330,共5页Tianjin Medical Journal

摘　　要：目的探讨艾立布林联合长春瑞滨+顺铂(NP)方案治疗晚期乳腺癌患者的临床效果。方法选取80例晚期乳腺癌患者,分为采用NP方案治疗的常规组和采用艾立布林联合NP方案治疗的联合组,每组40例。比较2组的临床获益率(CBR)、客观缓解率(ORR)和整体疗效;随访12个月,记录患者的无进展生存期(PFS),采用酶联免疫吸附试验检测治疗前、治疗4个周期后患者血清血管内皮生长因子(VEGF)A、VEGFB及VEGFC水平;按照常见不良事件评价标准评估患者的不良反应并分级。结果联合组ORR、CBR较常规组明显升高,联合组整体疗效优于常规组(P<0.05)。联合组PFS较常规组长(P<0.01);治疗后2组VEGFA、VEGFB、VEGFC水平均较治疗前降低,且联合组降低较常规组明显(P<0.05)。2组患者治疗期间主要的不良反应均为Ⅰ—Ⅱ级,主要有中性粒细胞下降、胃肠道反应、周围神经异常、乏力、肝功能损伤及脱发,发生率差异均无统计学意义。结论艾立布林联合NP方案治疗晚期乳腺癌能够提高患者CBR,降低VEGF表达水平,且安全性良好。Objective To investigate the clinical effect of aribulin combined with vinorelbine+cisplatin(NP)regimen in the treatment of advanced breast cancer patients.Methods Eighty patients with advanced breast cancer were selected and divided into the conventional group(treated with chemotherapy using NP regimen)and the combined group(treated with aribulin combined with NP regimen),with 40 cases in each group.The clinical benefit rate(CBR),objective response rate(ORR)and overall efficacy of the two groups were compared.Patients were followed for 12 months.The progression-free survival(PFS)was recorded in the two groups of patients.Serum levels of vascular endothelial growth factor(VEGF)A,VEGFB and VEGFC before treatment and 4 cycles after treatment were detected by enzyme-linked immunosorbent assay(ELISA).Adverse reactions of patients were evaluated and graded according to common adverse event evaluation criteria.Results The ORR and CBR of the combined group were significantly higher than those of the conventional group,and the overall curative effect of the combined group was better than that of the conventional group(P<0.05).PFS in the combination group was longer than that in the conventional group(P<0.01).After treatment,the levels of VEGFA,VEGFB and VEGFC in the 2 groups were lower than those before treatment,and the levels in the combined group were significantly lower than those in the conventional group(P<0.05).The main adverse reactions of 2 groups during treatment were grade Ⅰ to Ⅱ,including neutropenia,gastrointestinal reaction,peripheral nerve abnormality,fatigue,liver function injury and alopecia,with no statistical significance.Conclusion Aribulin combined with NP regimen in the treatment of advanced breast cancer can increase CBR and decrease VEGF expression level,with good safety.

关 键 词：乳腺肿瘤 长春瑞滨 顺铂 血管内皮生长因子类 艾立布林 临床获益率 

分 类 号：R737.9[医药卫生—肿瘤] R979.19[医药卫生—临床医学]